Storm Therapeutics announced a strategic collaboration with Alida Biosciences to use AlidaBio’s EpiPlex/EpiScout platforms to quantify transcript‑specific m6A RNA modifications in clinical samples from patients treated with Storm’s METTL3 inhibitor STC‑15. Financial terms were not disclosed. The work aims to map m6A dynamics, validate epitranscriptomic biomarkers and support patient selection strategies in ongoing Phase 1b/2 studies combining STC‑15 with PD‑1 inhibitor Loqtorzi for several solid tumors. Alida has commercial assays for epitranscriptome profiling and is developing multiplex tests to detect m6A, inosine and pseudouridine in a single workflow. Storm said the collaboration will help identify genes and cell types modulated by METTL3 inhibition and guide enrichment strategies in subsequent trials. The partnership highlights a growing emphasis on epitranscriptomic biomarkers as translational tools for emerging RNA‑modifying cancer therapies.